GlassScriptPhysician profile
John F Maher
NPI 1265561211
$1,507.68
in general payments reported to CMS, 2019-2025
12 companies · $34.63 in 2025
The $34.63 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $125 · 2021: $253 · 2022: $240 · 2023: $112 · 2024: $250 · 2025: $34.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $254.64 | 2021-2022 | |
| Glaukos Corporation | $251.02 | 2019-2020 | |
| Ivantis, INC | $147.53 | 2021 | |
| Allergan, INC. | $142.15 | 2019 | |
| Shire North American Group INC | $133.45 | 2019 | |
| Astellas Pharma US INC | $124.90 | 2024 | Izervay |
| Bausch & Lomb Americas INC. | $124.74 | 2024 | Miebo, Xiidra |
| Nobel Biocare USA | $92.59 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $90.46 | 2022 | |
| Abbvie INC. | $88.22 | 2023 | |
| Amgen INC. | $34.63 | 2025 | Tepezza |
| Alcon Vision LLC | $23.35 | 2023 | Hydrus Microstent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.